This is not the most recent version of the article. View current version (31 MAY 2013)

Intervention Protocol

Rituximab for thyroid-associated ophthalmopathy

  1. Neda Minakaran1,*,
  2. Rajni Jain2,
  3. Jimmy Uddin3,
  4. Daniel G Ezra4

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 10 AUG 2011

Assessed as up-to-date: 18 MAY 2011

DOI: 10.1002/14651858.CD009226

How to Cite

Minakaran N, Jain R, Uddin J, Ezra DG. Rituximab for thyroid-associated ophthalmopathy (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD009226. DOI: 10.1002/14651858.CD009226.

Author Information

  1. 1

    Central Middlesex Hospital, London, UK

  2. 2

    The Western Eye Hospital, London, UK

  3. 3

    Moorfields Eye Hospital NHS Foundation Trust, London, UK

  4. 4

    Moorfields Eye Hospital, Moorfields and UCL Institute of Ophthalmology BMRC, London, UK

*Neda Minakaran, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 10 AUG 2011


This is not the most recent version of the article. View current version (31 MAY 2013)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens


Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.